Diabetology, Vol. 6, Pages 158: Management of Type 2 and Post-Transplant Diabetes in Kidney Transplant Recipients: A Single-Center Clinical Experience with GLP-1 Receptor Agonists and SGLT-2 Inhibitors

Diabetology, Vol. 6, Pages 158: Management of Type 2 and Post-Transplant Diabetes in Kidney Transplant Recipients: A Single-Center Clinical Experience with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Diabetology doi: 10.3390/diabetology6120158 Authors: Ricardo E. T. Navarrete Joana C. Freitas Isabel Fonseca Ana Cunha Joao Roberto Sa La Salete Martins Objective: The aim was to characterize the […]

Alzheimer’s risk could rise with common condition affecting millions, study finds

The first study to evaluate the link between Alzheimer’s disease and body weight found a significant association. Researchers at Washington University Medicine in St. Louis, Missouri, discovered that Alzheimer’s blood biomarkers increased 95% faster in people with obesity than in non-obese individuals. The study, which was presented Tuesday at the annual meeting of the Radiological […]

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi

For Immediate Release Chicago, IL – December 5, 2025 – Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ and Sanofi SNY. Industry: Big Pharma Link: https://www.zacks.com/commentary/2799269/3-large-drug-stocks-to-watch-as-the-industry-shows-some-recovery The drug and biotech sector has recovered in the past couple of months after remaining muted for most of this year. The recovery began with […]

120 Capsules 50-in-1 Natural Activate GLP-1 Supplement only $9.49

Super Hot ~ Lowest EverGet 120 Capsules JonterKing 50-in-1 GLP-1 Supplement with Akkermansia & Vitamin B, GLP Support, Hunger & Metabolism, Natural Activate Probiotic and Prebiotic Formula for only $9.49. Tagged as: 607603459596 | Vitamins & Supplement Click here for complete deal detail and steps on how to get it. Share this deal with your […]

GLP-1RAs shown to reduce risk of cardiovascular death

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with chronic cardiovascular, kidney, and metabolic diseases. Those studies focused mainly on patients with singular diagnoses, but these conditions often overlap.

2 FTSE 100 shares I like better than Rolls-Royce right now

Over the past three years, Rolls-Royce (LSE:RR) shares have mounted the sort of comeback story normally reserved for Hollywood movies. It has certainly benefitted my portfolio, reminding me that FTSE 100 stocks can also sometimes serve up Tesla-type returns. However, while I’m still bullish long term, the market appears well up to date with the […]